Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
0.9303
+0.1081 (13.15%)
Feb 6, 2026, 4:00 PM EST - Market closed
Senti Biosciences Employees
Senti Biosciences had 34 employees as of December 31, 2024. The number of employees decreased by 14 or -29.17% compared to the previous year.
Employees
34
Change (1Y)
-14
Growth (1Y)
-29.17%
Revenue / Employee
n/a
Profits / Employee
-$1,473,618
Market Cap
24.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 34 | -14 | -29.17% |
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| IGC Pharma | 70 |
| Boundless Bio | 64 |
| Daré Bioscience | 23 |
| BriaCell Therapeutics | 16 |
| Skye Bioscience | 16 |
| Rallybio | 15 |
| Serina Therapeutics | 13 |
SNTI News
- 5 days ago - Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 - GlobeNewsWire
- 25 days ago - Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - GlobeNewsWire
- 4 weeks ago - Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - GlobeNewsWire
- 2 months ago - Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET - GlobeNewsWire
- 3 months ago - Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December - GlobeNewsWire